Contezolid acefosamil (sodium)

Contezolid acefosamil sodium (MRX-4), a new and orally active oxazolidinone, is an antibiotic in study for complicated skin and soft tissue infections (cSSTI) caused by resistant Gram-positive bacteria. Contezolid acefosamil sodium (MRX-4) markedly reduces potential for myelosuppression and monoamine oxidase inhibition (MAOI) [1][2].

Product Specifications

CAS Number

[1807365-35-0]

Product Name Alternative

MRX-4 (sodium)

UNSPSC

12352005

Target

Antibiotic; Bacterial; Monoamine Oxidase

Type

Reference compound

Related Pathways

Anti-infection; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/contezolid-acefosamil-sodium.html

Purity

95.19

Solubility

DMSO : 180 mg/mL (ultrasonic)

Smiles

FC(C(F)=C1N(C=C2)CCC2=O)=C(N(C(O3)=O)C[C@@H]3CN(C4=NOC=C4)[P](OC(C)=O)(O[Na])=O)C=C1F

Molecular Formula

C20H17F3N4NaO8P

Molecular Weight

552.33

References & Citations

[1]Junzhen Wu, et al. Evaluation of the Effect of Contezolid (MRX-I) on the Corrected QT Interval in a Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study in Healthy Chinese Volunteers. Antimicrob Agents Chemother. 2020 May 21;64 (6) :e02158-19.|[2]Mikhail F Gordeev, et al. New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile. J Med Chem. 2014 Jun 12;57 (11) :4487-97.|[3]Carolyn Shoen, et al. In Vitro and In Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2018 Jul 27;62 (8) :e00493-18.